Melanoma patients in stage III have a considerable recurrence rate. The 10‐year survival in
this stage depends on the number and size of affected nodes. Currently, there is no optimal …

In the follow-up of melanoma patients, there is still a need for an optimal serum marker to
discover recurrent disease at an early stage. Melanoma inhibitory activity (MIA) has been …

Melanoma inhibitory activity (MIA) protein was identified in significant quantities in primary
and metastatic malignant melanomas, where it has an important role in promoting tumor …

This analytic (phase II) study aimed to investigate the hypothesis that the decline in serum
melanoma-inhibiting activity (MIA) levels following initiation of treatment might have …

Melanoma-inhibiting activity (MIA) is a 107 amino-acid protein secreted from melanoma
cells and frequently detectable at high concentration in the serum of patients with advanced …

One of the principal applications of tumour markers is the early detection of recurrent
disease in the follow-up of patients. In the study described here, we compared the …

Melanoma inhibitory activity (MIA) was originally identified as an 11 kDa protein secreted
from malignant melanoma cells. We have shown that MIA is strongly expressed in …

Malignant melanoma is a highly aggressive cancer with a very poor prognosis after the
onset of metastasis. We have previously demonstrated that the protein melanoma inhibitory …

Background. Cutaneous malignant melanoma (CMM) is a heterogeneous disease,
acknowledged for its lack of predictability regarding clinical evolution. In order to appreciate …

Background: Serum levels of melanoma markers may have a role in monitoring disease
evolution in metastatic melanoma. Patients and Methods: Serial measurements of …